Main menu button

Carlsquare advised curea medical on the sale to Mérieux Equity Partners

Carlsquare advised curea medical (“curea”), a specialist in advanced wound care solutions and subsidiary of McAirlaid’s, to Mérieux Equity Partners (“MxEP”), a healthcare-focused private equity firm. This transaction marks a significant step in curea medical’s continued growth and innovation while expanding its global reach.

curea medical, a German manufacturer, specializes in innovative wound care solutions, particularly superabsorbent dressings with proprietary SuperCore® technology for superior fluid management. Serving homecare companies, distributors and retailers, pharmaceutical wholesalers and hospitals, curea is a key player in advanced wound care through continuous innovation and high-quality manufacturing.

Mérieux Equity Partners is a leading European healthcare-specialized investment firm with Venture Capital and Buyout platforms. supporting companies ranging from start-ups to established leaders. Leveraging deep expertise and a vast network, MxEP supports companies with ambitious growth plans and transformative healthcare innovations.

McAirlaid’s manufactures high-performance, adhesive- and binder-free airlaid nonwovens for healthcare, food packaging, and hygiene. Known for innovation and sustainability, it develops chemical-free, highly absorbent solutions that set industry standards.

“Over the past 10 years, curea medical has developed into an established manufacturer of wound dressings for the German and several international markets. To take this development to the next level, we have spent the past few months searching for a new partner who can support our next steps. We have found this partner in Mérieux Equity Partners, and I am very much looking forward to our continued collaboration. I would also like to thank Caspar von Stauffenberg and his team at Carlsquare for their outstanding M&A support throughout this process.” – Dr. Andreas Bolz, CEO, curea medical

“We are thrilled to partner with curea and its management team, as well as McAirlaid’s, to propel the company into its next growth phase. Curea stands out for its cutting-edge solutions in advanced wound care, and we see significant growth potential across Europe. Our ambition is to build a leading European player in superabsorbent dressings, leveraging curea’s technological expertise and state-of-the-art manufacturing capabilities in Germany.– Jaana Grüter and Theodor Wuppermann, Partners, Mérieux Equity Partners

Carlsquare acted as the exclusive financial advisor to curea medical.

de
curea medial GmbH
fr
Merieux Partners
de
McAirlaid's
Caspar Graf Stauffenberg
Caspar Graf Stauffenberg LinkedIn
Managing Partner
Lukas Moritzen
Lukas Moritzen
Senior Associate